Shots:

• BMS and Nektar Therapeutics are terminating their cancer drug research alliance after the failure of Bempeg + Opdivo in RCC and bladder cancers. The companies have decided to discontinue both the studies and all other ongoing studies in the program
• The P-III PIVOT-09 study showed that the combination therapy vs TKI did not meet its prespecified boundary for statistical significance in RCC patients. Additionally, P-II PIVOT-10 study also failed to reach an efficacy threshold in UC
• These disappointing results come one month after the drug combo failed a pivotal melanoma clinical trial

Ref: PR Newswire | Image: BMS